KLK3 and prostate cancer: The aim of the experiments is to identify a suitable set of features which would, as a combination, deliver an immunophenotypic “fingerprint” for determining whether an individual with Prostate-Specific Antigen (PSA) levels below 20 ng ml−1 has prostate cancer in the absence of definitive biopsy-based evidence.